BEIJING, April 14, 2026 /PRNewswire/ — A news report from chinadaily.com.cn:

Artificial intelligence is reshaping industries worldwide while widening the digital divide between regions, and Hong Kong is well-positioned to foster greater AI collaboration across the Asia-Pacific and promote more inclusive digital development.

Policymakers and industry leaders made the remarks at the World Internet Conference Asia-Pacific Summit, which opened at the Hong Kong Convention and Exhibition Centre on Monday.

Zhuang Rongwen, director of the Cyberspace Administration of China and chairman of the World Internet Conference, said the Hong Kong Special Administrative Region enjoys unique advantages in advancing digital exchange and cooperation, given its role as an international hub for shipping, trade and finance, as well as its position as a gateway connecting China with the world.

“Countries and regions across the Asia-Pacific have made digital transformation a common choice to capture new growth opportunities and sharpen their competitive edge,” Zhuang said, adding that the digital economy has become “a bright spot” in regional cooperation.

“China remains committed to sharing opportunities arising from digital development with other nations,” he said.

Hong Kong Chief Executive John Lee Ka-chiu said hosting the event underscores the SAR’s growing prominence as an international innovation and technology hub and reinforces its integration into national development plans.

“Hong Kong looks forward to working with partners around the region, and across the world, to help shape a digital future built on openness, innovation and inclusivity,” he added.

According to Lee, the Hong Kong Park of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone, which opened in December, has attracted more than 70 tenants in sectors including AI and data science.

Covering 0.87 square kilometers in Hong Kong and 3.02 sq km on the Shenzhen side, the cooperation zone is exploring the movement of research materials and other innovation resources across the boundary, he said.

AI is central to Hong Kong’s innovation and technology development, Lee said, noting that the city ranked third in the Global AI Competitiveness Index, after New York and London.

But he cautioned that the power of AI must be balanced by its responsible and inclusive use, describing technology as a tool that “could function well only with a spirit of cooperation and creativity”.

John Hoffman, CEO of GSMA Ltd, echoed the view, emphasizing that “the future of AI won’t be decided by one organization, one industry, one region or one person”, and that cooperation could help close the digital and economic divide.

He said China, including the Hong Kong SAR, “has a unique position” to play a leadership role, and its experience in innovation can be shared globally.

Describing AI as entering a new frontier marked by the rise of AI agents, Hong Kong Secretary for Innovation, Technology and Industry Sun Dong said the Hong Kong SAR government is closely monitoring the technology’s evolution.

Although agents could broaden AI’s application across industries, they will also inevitably raise new security concerns, Sun said. “The SAR government’s approach toward AI agents is clear — development must go hand in hand with regulation.”

Samuel Migal, minister of investments, regional development and informatization of Slovakia, said that in the face of advancements in digital technology and AI, the common challenge is the need to establish new governance frameworks.

While different countries and regions may adopt varying regulatory models, “fragmentation cannot be the outcome”, he said.

Debut Public Appearance Since Strategic Merger with NAMI Demonstrates Strengthened Research Capabilities

HONG KONG, April 14, 2026 /PRNewswire/ — The Hong Kong Applied Science and Technology Research Institute (ASTRI) is participating in the InnoEX 2026, which is taking place at the Hong Kong Convention and Exhibition Centre (HKCEC) from 13 to 16 April. This participation marks ASTRI’s first public engagement following its strategic merger with the Nano and Advanced Materials Institute (NAMI) on 1 April 2026, highlighting its enhanced research and development (R&D) capabilities. The merger brings together pioneering ICT technologies and advanced materials expertise, creating strong synergies that drive greater innovation and enable more impactful practical applications.

Under the theme “Leading Innovation • Breaking Boundaries”, ASTRI’s booth showcases 40 market-ready innovations across four key areas: Healthcare, Food Technology, Smart Living, and Mobility Technology. Highlights include advancements in construction and property management technology, artificial intelligence, low-altitude economy technology, electronics and batteries, green materials, nanotechnology and sustainability-led innovations – all contributing to the growth of smart cities.

Driving Innovation for Economic Growth

Ir Prof Sunny Lee, Board Chairman of ASTRI, described the merger of ASTRI and NAMI as a significant milestone for Hong Kong’s innovation and technology (I&T) sector, injecting fresh impetus into the city’s high-quality economic development. “ASTRI will continue to drive technology transfer and commercialisation through R&D collaborations and licensing, while further fostering partnerships among the I&T ecosystem. This will accelerate the journey from lab to market, benefiting industries and society at large. Together, we aim to build a smarter, greener and more resilient future, strengthening Hong Kong’s position as a global I&T hub.”

He also emphasised ASTRI’s commitment to collaborate with global partners leveraging Hong Kong’s unique “super-connector” role, showcasing the city’s R&D excellence on the world stage.

Enhanced Capabilities for Creating Total Solutions

Ir Dr Ted Suen, Chief Executive Officer of ASTRI, highlighted the institute’s expanded research capabilities following the merger. “By uniting advanced technologies with materials science, we are delivering more innovative and holistic solutions to enhance our clients’ efficiency and competitiveness. We are delighted to participate in this mega event, showcasing ASTRI’s post-merger capabilities to global stakeholders across government, industry, academia, research and investment, while exploring new avenues for collaboration.”

He added that the breadth and depth of technologies on display at this year’s InnoEx have set a new record, underscoring the synergies created by the merger. He cited examples such as ASTRI’s advanced 5G-enabled remote-control tower crane systems, its Edison Awards 2026-finalist precision positioning technology, and high-strength lightweight concrete designed for modular integrated construction (MiC) as innovations transforming the construction industry. “This integrated solution reduces structural weight by 25%-40%, significantly lowering transportation and lifting costs while improving installation accuracy. Paired with energy-saving Nano-curtain coating and carbon-neutral biochar concrete, it further advances the sustainability of construction projects,” he explained.

Integrating Cutting-Edge Technology with Advanced Materials

In addition, ASTRI has developed a comprehensive fall prevention solution for the elderly, combining behavioural prediction, alert systems, and protective materials to enhance safety. “Leveraging behavioural sensing analytics and pressure detection technology, our system effectively predicts the likelihood of falls and issues early warnings. This is complemented by an impact-absorbing intelligent floor mat that disperses and converts the force of a fall into heat energy, reducing the risk of injury. Seniors can also wear the comfortable and form-fitting hip protectors to further minimise the risk of fractures.”

ASTRI has also blended advanced materials with innovative technologies to create breakthrough green energy solutions. These not only improve energy efficiency and storage but also enhance resilience to extreme weather and stabilise energy supply, driving the sustainable development of smart cities. Other key innovative solutions include:

Healthcare

• CHIMP: Continuous Health Information Monitoring Patch: Co-developed with the Hospital Authority and Tin Shui Wai Hospital, this wearable device collects real-time vital data from hospitalised patients, enhancing care efficiency and patient safety. It won the Gold Award in the Smart Living (Smart Healthcare) category at the Hong Kong ICT Awards 2025.

• Probiotics Revitalising System (PRS): Probiotic strains with demonstrated skin-health benefits are rendered dormant using our PRS technology, then revitalised upon topical application on skin to help promote a balanced microbiome.

Food Technology

• Intelligent Tactile Sensing for Fruit Ripeness Detection: Advanced sensing technology has been brought from the lab to farms and food processing facilities, ensuring fruits are harvested and delivered at peak ripeness and quality.

• 3D Printable Formulations for Texturised Food: It enables the 3D printing of nutritious care food with definite shape and layer fidelity, fabricating whole meat and fillets that can fulfill the protein needs of the elderly, alongside biting and chewable pleasure.

Smart Living

• Embodied Intellibot System: Powered by Vision-Language Models (VLMs), these robots can perceive environments, understand and execute human instructions. Suitable for home, industrial, and healthcare applications, they ensure safety and reliability.

• 55°C+ High-temperature Resistant Li-ion Batteries: Machine learning-optimised electrolyte solvents & additives cut 80% standby loss, extend cycle life by 25% under high temperature, ideal for outdoor energy storage in high-temperature environments.

Mobility Technology

• Generative Pretrained Model for Multi-Modal Traffic Data: Revolutionising urban traffic management system with artificial intelligence.
• Self-Levelling Backfill Materials: Traditional road damage and collapses caused by inadequate soil compaction are mitigated with this self-levelling, self-compacting backfill material. It can be continuously pumped into trenches, improving construction efficiency and road quality.

About ASTRI

Founded in 2000 by the HKSAR Government, Hong Kong Applied Science and Technology Research Institute (ASTRI) is the city’s largest government-funded R&D center. Committed to transforming high-impact research into practical innovations, ASTRI drives market-driven, interdisciplinary advancements across sectors, including Smart City, FinTech, Digital Health and Life Sciences, New Industrialisation and Intelligent Manufacturing, Application-Specific Integrated Circuits (ASIC) and Advanced Electronics, New Energy and Energy Storage, and Green and ESG Technologies. Following its merger with the Nano and Advanced Materials Institute, ASTRI has further strengthened its capabilities, with over 1,500 global patents and 2,200 successful cases of technology transfer. Recognised with numerous international awards, ASTRI continues to nurture top I&T talent and foster collaborations among the I&T ecosystem, contributing to Hong Kong’s high-value economic development.

Photos Download: https://bit.ly/4btCLJD

MELBOURNE, Australia and INDIANAPOLIS, Ind., April 14, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) (“Telix“) today launches an offering of US$550 million convertible notes due 2031 to be issued by its wholly-owned subsidiary, Telix Pharmaceuticals (Investments) Inc. (the “Issuer“), and guaranteed by Telix and Telix Pharmaceuticals (US) Inc. (the “Offering“). The convertible notes, also referred to as “convertible bonds” (“Convertible Bonds“), are convertible into fully paid ordinary shares in Telix (“Ordinary Shares“).

Managing Director and Group CEO, Dr. Christian Behrenbruch, said: “The refinance of the existing Convertible Bonds represents our proactive approach to capital management. The new Convertible Bonds will continue to provide the business with cost effective financing.”

The new Convertible Bonds represent attractive, low-cost financing to Telix and are non-dilutive until any potential future conversions occur. The initial conversion price will be at a premium to Telix’s current share price.

After deduction of commissions, professional fees and other administrative expenses, it is intended that the net proceeds will be used to repurchase the existing convertible bonds due 2029 (“Existing Convertible Bonds“). Any funds raised above that required for the repurchase of the Existing Convertible Bonds will be applied to general corporate purposes.

Convertible Bonds Offering

• It is intended that the Convertible Bonds will be listed on the Official List of Singapore Exchange Securities Trading Limited (“SGX-ST“)
• The Offering is being marketed to eligible investors with the final terms of the Convertible Bonds to be determined via a bookbuild process expected to be completed prior to market open on Wednesday, 15 April 2026
• Concurrent with the Offering, a delta placement of Ordinary Shares will be executed to facilitate hedging activity by investors in relation to the Convertible Bonds. The clearing price per Ordinary Share under the delta placement will be used as the reference share price for the Convertible Bonds
• More details on the key terms of the Convertible Bonds are provided in the table below

Stock Borrow Facility

To assist the implementation of the Convertible Bonds Offering, Elk River Holdings Pty Ltd as the trustee for The Behrenbruch Family Trust^[1] (“Stock Lender“) intends to enter into a stock lending agreement with an affiliate of J.P. Morgan (“Stock Borrower“) pursuant to which the Stock Lender will lend a certain number of Ordinary Shares to the Stock Borrower, and the Stock Borrower will be required to return the borrowed Ordinary Shares to the Stock Lender pursuant to the terms of the agreement (“Stock Borrow Facility“).

Concurrent Repurchase

Additionally, Telix is conducting a reverse bookbuilding process to receive indications of interest from holders of the Existing Convertible Bonds on a repurchase of the outstanding Existing Convertible Bonds (“Concurrent Repurchase“). The number of Existing Convertible Bonds to be repurchased and the purchase price will be determined by the reverse bookbuilding process.

Adviser

J.P. Morgan Securities plc (“J.P. Morgan“) is Sole Bookrunner on the Offering and Sole Dealer Manager on the Concurrent Repurchase.

Key terms of the Convertible Bonds

About Telix Pharmaceuticals Limited

Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan, Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors.  

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including Australia, Singapore, and the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and  TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Neither this announcement nor any copy hereof may be taken into or distributed in the United States.

The information contained in this announcement is not for distribution, directly or indirectly, in or into the United States. The Convertible Bonds, the guarantees and the Ordinary Shares to be issued upon conversion of the Convertible Bonds have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act“) or the securities laws of any state or other jurisdiction of the United States and they may not be offered or sold, resold, transferred or delivered, directly or indirectly, within the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S under the Securities Act) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state or local securities laws. The Convertible Bonds and the guarantees are being offered and sold solely outside the United States in an “offshore transaction” as defined in, and in reliance on Regulation S under the Securities Act.

Nothing in this announcement or anything attached to it shall form the basis of any contract or commitment.

The Concurrent Repurchase is not being made and will not be made, directly or indirectly, in or into the United States. This includes, but is not limited to, facsimile transmission, electronic mail, telex, telephone, the internet and other forms of electronic communication. The Existing Convertible Bonds may not be tendered in the Concurrent Repurchase by any such use, means, instrumentality or facility from or within the United States or by persons located or resident in the United States as defined in Regulation S of the Securities Act. Any purported tender of Existing Convertible Bonds made by a person located in the United States will not be accepted.

This communication may not be distributed to the press or other media or forwarded, photocopied, passed on or, in any other manner, transmitted to any other person. Non-compliance with the foregoing may constitute a violation of law. This information is subject to change.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.